Tuesday, December 18, 2012 11:22:26 AM
The Momenta court additionally held
that, for purposes of Section 271(e)(1), information
may be deemed “submitted” to
FDA if it is preserved in records that FDA
regulations require a drug manufacturer to
make available for inspection by FDA on
request. See 686 F.3d at 1357. We express
no view on the correctness of that conclusion
or of the court of appeals' ultimate
disposition of Momenta.
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
Cannabix Technologies Announces Commercial Launch of Marijuana Breath Test (MBT) • BLOZF • Mar 16, 2026 8:37 AM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM
Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM
